Oramed Reports Last Patient Left Clinic in Phase 2a FDA Trial of ORMD-0801 Oral Insulin Capsule

Oramed Pharmaceuticals ORMP announced today that the last patient has left the clinic from its U.S. FDA Phase 2a safety study for ORMD-0801, an oral insulin capsule based on the Company's platform Protein Oral Delivery (POD™) technology. The Phase 2a trial, which enlisted 30 type 2 diabetes patients in an in-clinic setting for a seven-day period, was implemented in response to FDA feedback requesting a safety study on ORMD-0801 prior to initiating a larger multi-center trial in the US. "We are thrilled to announce the last patient out of our Phase 2a clinical trial under the FDA. We look forward to announcing the results," said Oramed CEO Nadav Kidron. About ORMD-0801 Oral Insulin Oramed's ORMD-0801 is an orally ingestible insulin capsule indicated for the early stages of type 2 diabetes, when it can still slow the rate of degeneration of the disease by providing additional insulin to the body and allowing pancreatic respite. Moreover, orally administered insulin has the potential benefit of enhanced patient compliance at this crucial stage as well as the advantage of mimicking insulin's natural location and gradients in the See full press release